Publications by authors named "J D McCafferty"
The evolving development landscape of biotherapeutics and their growing complexity from simple antibodies into bi- and multi-specific molecules necessitates sophisticated discovery and engineering platforms. This review focuses on mammalian display technology as a potential solution to the pressing challenges in biotherapeutic development. We provide a comparative analysis with established methodologies, highlighting key aspects of mammalian display technology, including genetic engineering, construction of display libraries, and its pivotal role in hit selection and/or developability engineering.
View Article and Find Full Text PDFPurpose: Interhospital transfer of critically injured patients to a major trauma service reduces preventable death in major trauma. Yet some of those transferred die without intervention. These 'futile' interhospital trauma transfers (IHTs), and other potentially avoidable IHTs place enormous stress on families of trauma victims, can delay care, and incur great cost to public health resources.
View Article and Find Full Text PDFArticle Synopsis
- Peripheral T cell lymphomas are aggressive cancers with a poor prognosis and pose challenges for immunotherapy due to the lack of distinguishing antigens between healthy and cancerous cells.
- Researchers have used advanced computational biology to develop a TRBC2-specific antibody (KFN), which, alongside a previously created TRBC1-specific antibody (Jovi-1), offers a way to target a wider range of T cell malignancies.
- The combination of these antibodies enables the creation of specialized chimeric antigen receptor-T cells that may prove effective in treating various T cell cancers in preclinical tests.
Article Synopsis
- A good developability profile is important for making effective biological drugs and helps avoid problems later in the process.
- We review key properties that can be checked early, like the source of the drug and how it behaves in the body.
- We also talk about methods to find the best drug options and the differences between drugs given by injection and those taken by mouth.
Snakebite envenoming continues to claim many lives across the globe, necessitating the development of improved therapies. To this end, broadly-neutralizing human monoclonal antibodies may possess advantages over current plasma-derived antivenoms by offering superior safety and high neutralization capacity. Here, we report the establishment of a pipeline based on phage display technology for the discovery and optimization of high affinity broadly-neutralizing human monoclonal antibodies.
View Article and Find Full Text PDF